Hong Kong stock AI sector value new wave: iFlytek Medical (02506) released the first national medical deep reasoning model Starlight Medical Big Model X1.

Since the beginning of 2025, the Hong Kong stock market has continued to strengthen under the dual drivers of breakthroughs in AI technology and the revaluation of Chinese assets. In particular, the emergence of the domestic large model DeepSeek has led to a reevaluation of Chinese technology companies by global capital. Recently, Iflytek Co., Ltd. announced the comprehensive upgrade of the Spark Deep Inference Model X1, inspiring a strategic reassessment of the leading domestic AI medical infrastructure in the secondary market based on the Spark X1 in the medical field (02506). As the only domestic medical deep inference large model trained with domestic computing power, the Spark Medical X1 model has surpassed GPT-4o and DeepSeek R1 in medical tasks such as diagnostic recommendations and health consultations, marking a major technological breakthrough in the field of AI medicine. Spark Medical X1 is currently the only domestically trained medical vertical model based on platforms such as Huawei Ascension, leveraging Iflytek Medical's billion-level medical knowledge base and desensitized diagnostic data to increase the accuracy of diagnostic recommendations to the level of specialist physicians, reducing the model's "hallucination rate" by 10%. Iflytek Medical has launched a range of innovative products based on the Spark Medical X1, including the personal health assistant Iflytek Xiaoyi, and the Spark Medical all-in-one machine. These products not only enhance user experience but also provide efficient and secure integrated solutions for medical institutions and regions. On the user side, the health assistant Iflytek Xiaoyi can deeply interpret personal health records and provide personalized advice; on the medical institution side, the model supports applications for 20 medical scenarios such as medical record generation and intelligent follow-up, and together with Huawei has launched the "Spark Medical all-in-one machine," achieving localized deployment of data, with a 40% increase in inference efficiency. International institutions such as Deutsche Bank and Goldman Sachs are increasingly optimistic, believing that China's competitiveness in the field of AI will reshape the global industrial chain, and the "valuation discount" of Chinese stocks is expected to gradually disappear. This rapid development of AI technology in China has triggered a revaluation of Chinese assets and has had a positive impact on the Hong Kong stock market. Benefiting from the active promotion of AI in pharmaceuticals and medical innovation research and development, the corresponding sectors in the Hong Kong stock market have experienced significant growth. In February 2025, the Hong Kong biomedical index rose by 15.99%, and the smart healthcare index rose by 32.15% as of February 19, with a 72.73% increase in the past six months. I...